- Home
- GCDT vs BCAB Comparison
GCDT vs BCAB Comparison
Compare GCDT & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GCDT | BCAB |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GCDT | BCAB |
|---|---|---|
| Price | $0.36 | $3.43 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 110.4K | 38.8K |
| Earning Date | 05-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.12 |
| 52 Week High | $5.32 | $6.52 |
Technical Indicators
Market Signals| Indicator | GCDT | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 28.79 | 42.09 |
| Support Level | N/A | $3.28 |
| Resistance Level | $0.66 | $4.24 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 7.00 | 10.23 |
Price Performance
Historical ComparisonAbout GCDT Green Circle Decarbonize Technology Limited Ordinary Shares
Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.